Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it is discontinuing its clinical development program for tozadenant, an investigational treatment ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE